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ABSTRACT 
The present study aimed towards the development of active delivery system for management of hypertension. The Orodispersible 
tablets (ODTs) containing Telmisartan was developed in order to accomplish enhanced solubility leading to better bioavailability 
profile. Different ratios, of Telmisartan and PEG 6000 i.e. 1:1, 1:2, 1:3, 1:4 and 1:5 were selected for the formulation of ODT system. A 
batch process was adopted for the preparation of solid dispersion with each combination of drug and polymer and the finally 
compressed as tablets by direct compression technique. For the preformulation perspective materials were scrutinized on the basis 
of solubility profile, drug content, Fourier Transform Infrared (FTIR) spectroscopy and Differential scanning calorimetry (DSC). The 
drug polymer ratio 1:4 was selected for further compression process. The prepared batches of ODTs were characterized for 
micromeritic study, thickness, hardness, weight variation, wetting time, disintegration time, drug content and in vitro drug release 
profile. The evaluation data for all batches was satisfactory out of them formulation TF3 containing 6% kyron T-314 showed the 
best results with a value of 29.3 sec and 24.1 sec for wetting and disintegration, respectively. This formulation showed superior drug 
release of 99.93% over a period of 30 minutes. 
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INTRODUCTION 
Over the years, hypertension is a mammoth challenge for 
the health professionals.  Telmisartan is a BCS class-IInd 
drug, is very poorly soluble in water, which results in the 
slow dissolution and hence low bioavailability when 
administered orally (~41%)1-3.The absolute bioavailability 
of Telmisartan is dose-dependent. The bioavailability of 
Telmisartan increased from 41% to 59%, when the dose 
was increased from 40 mg to 160 mg respectively. The 
solid dispersion approach can be successfully used in the 
improvement of solubility of poor water soluble drugs. A 
number of drugs have been shown to exhibit better 
aqueous solubility and dissolution characteristics in the 
form of solid dispersion4,5. 
Telmisartan is used in the treatment of hypertension. The 
action of Telmisartan is done by binding to binding to the 
angiotensin II type 1 receptors, resulting in the inhibition 
of angiotensin II on vascular smooth muscles, so it is a 
angiotensin II receptor antagonist6. Problems like low 
solubility and bioavailability conquered by the utilization 
of solubility enhancement technique i.e. solid dispersion 
and novel formulation approach i.e. ODTs. ODTs 
disintegrate or dissolve very rapidly in mouth as they come 
into the contact with saliva, without any need of extra 
water. This unique asset of ODTs combines the advantages 
of both liquid and conventional dosage form, for oral 
administration. Rapid disintegration of ODTs within the 
oral cavity fosters pregastric absorption through buccal 
mucosa, pharyngeal mucosa and oesophagus. Due to this 
pregastric absorption first pass metabolism is bypassed 
and accounts for the enhanced bioavailability of the 
incorporated therapeutic agent. Additionally, the problem 
of dysphagia especially in paediatric and geriatric 
individuals is triumphed over by the development of 
ODTs7. These exceptional possessions put the ODTs on the 
upper hand in comparison to conventional dosage forms in 
terms of enhanced the patient compliance with better 
safety and efficacy 8,9. 
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The present course of study attempts to enhance the 
solubility of Telmisartan by solid dispersion technique with 
polyethylene glycol (PEG 6000) and compressed it as ODT 
in order to develop an effective treatment for the 
management of Hypertension10-12. 
MATERIALS AND METHODS 
Materials 
Telmisartan was received as a gift sample from Skymap 
Pharmaceuticals, Roorkee, India. Sodium starch glycolate, 
croscarmellose sodium was a kind gift from Maple biotech 
pvt. Ltd. Pune, Maharashtra and kyron T-314 was kindly 
donated by Corel pharma chem., Ahemdabad, Gujrat. Poly 
ethylene glycol (PEG 6000), Micro crystalline cellulose was 
purchased from SD fine chemicals; Poly vinyl pyrollidone 
(PVP), magnesium stearate, and talc were purchased from 
Himedia laboratories Ltd. All other chemicals used were of 
analytical grade. 
Methods 
Preparation and characterization of solid dispersion 
Solid dispersion of Telmisartan and PEG 6000 was 
prepared using different ratios i.e. 1:1, 1:2, 1:3, 1:4, 1:5 by 
conventional solvent evaporation method13. Briefly, 
Telmisartan and PEG 6000 were weighed accurately in 
different ratios and mixed uniformly. This mixture was 
dissolved in ethanol with continuous stirring and subjected 
to solvent evaporation by heating at 40 0C. The resultant 
solid dispersions were dried for 24 hr. in desiccator. Dried 
mass was scraped, crushed, pulverized and passed through 
sieve (# 60) 
Solubility study 
Samples (pure drug and solid dispersion) equivalent to 10 
mg of Telmisartan were added to 10 ml each of distilled 
water and PBS (pH 6.8). These dispersions were shaken 
well and kept for 24 h. The solution was filtered through 
whatman filter paper (#41) and spectrophotometrically 
analysed at 296 nm using UV-Visible spectrophotometer 
(UV-1800, Shimadzu, Japan). 
Infrared spectroscopy 
IR spectroscopy of Telmisartan, PEG 6000 and their solid 
dispersion was performed on Fourier transform infrared 
spectroscopy (FTIR 8400S, Shimadzu, Japan). Drug, carrier 
and solid dispersion was mixed separately with KBr (95:5) 
and placed in to sample holder. The scanning range and 
resolution was 400-4000 cm-1 and 4 cm-1, respectively. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) measurements was 
performed for Telmisartan, PEG 6000 and its solid 
dispersion using DSC instrument (JADE DSC-6, PYRIS, USA) 
equipped with a liquid nitrogen sub ambient accessory. 
The instrument operated under nitrogen purge gas at a 
rate of 20 ml/min. Samples (3-6 mg) were weighed in open 
aluminium pans and scanned at a speed of 100C/min from 
30-3000C. 
Drug content analysis 
Accurately weighed quantity of solid dispersion 
(theoretically equivalent to 10 mg of Telmisartan) was 
dissolved in small amount of ethanol and volume was made 
up to 10 ml with PBS (pH 6.8). The solution was sonicated 
for 5 min. Solution was filtered through whatman filter 
paper (#41). The sample was assayed by UV-
spectrophotometer (UV-1800, Shimadzu, Japan) at 296 nm. 
Formulation of ODTs using Solid Dispersion 
Solid dispersion of Telmisartan and PEG 6000 is 
compressed in to Orodispersible tablets. The TSD4 
formulation containing 1:4 ratio is selected on the basis of 
solid dispersion characterization i.e. solubility, FTIR, DSC, 
and drug content for tablet preparation. Direct 
compression technique was utilized for the compression of 
solid dispersion of Telmisartan and PEG 6000 for the 
development of ODTs. All ingredients (solid dispersion 
equivalent to 20 mg Telmisartan and other excipients) 
were mixed properly and the blends were passed through 
sieve (# 40). The powder blend was compressed into 
tablets on a single punch tablet machine using round shape 
flat punch having diameter of 12 mm (Rolex machineries, 
Mumbai, India). The tablet weight was adjusted to 200 mg 
(Table 1). kyron T-314, croscarmellose sodium and Sodium 
starch glycolate used as disintegrating agent. While 
microcrystalline cellulose (MCC) used as diluents and 
magnesium stearate was used as lubricant. 
 
Table 1: Composition of Various Orodispersible Tablets of Telmisartan 
S. 
No. 
Ingredients (mg)                                    Formulations  
TF1 TF2 TF3 TF4 TF5 TF6 TF7 TF8 TF9 
 1. Solid dispersion( Eq. to 20 mg 
Telmisartan) 
100 100 100 100 100 100 100 100 100 
2.  Kyron T-314 8 10 12 - - - - - - 
3. Croscarmellose sodium - - - 8 10 12 - - - 
4. Sodium starch glycolate - - - - - - 8 10 12 
5. Polyvinylpyrollidone (PVP) 10 10 10 10 10 10 10 10 10 
6. Microcrystalline cellulose (MCC) 73 71 69 73 71 69 73 71 69 
7. Magnesium stearate 4 4 4 4 4 4 4 4 4 
8. Talc 5 5 5 5 5 5 5 5 5 
 Total weight 200 200 200 200 200 200 200 200 200 
 
Evaluation of ODTs 
Micromeritic studies 
The powder mixture of formulations was characterized for 
their micromeritic properties, such as bulk density, tapped 
density, compressibility index, angle of repose and hausner 
ratio. An accurately weighed quantity of the powder 
mixture of formulations was carefully poured into the 
graduated cylinder and volume was measured, which is 
called bulk volume the graduated cylinder was closed with 
lid and set into the tap density tester. The density 
apparatus was set for 100 tabs, noted as tapped volume14. 
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Bulk density, tapped density, % compreesibility index and 
hausner ratio were calculated using following formulae 
Bulk density = W/V0, and Tapped density = W/Vf  
Where, W= Weight of the powder V0 = Initial volume, Vf = 
final volume 
Carr’s index (%) = [(TD-BD) × 100]/TD 
Angle of repose of the powder was determined by the 
funnel method. It reflects the flow ability of a powder. The 
accurately weighed powder mixture of formulations was 
taken in the funnel. The height of the funnel was adjusted 
in such a way that the tip of funnel just touched the apex of 
the heap of the powder mixtures of formulations. The 
powder mixtures of formulations were allowed to flow 
through the funnel freely on to the surface. The diameter of 
the powder cone was measured and angle of repose was 
calculated using the following equation given below. 
Tan θ = h/r 
Where, h= Height of pile and r= Radius of the pile 
Thickness and hardness 
The tablet thickness was measured using digital Vernier 
caliper. Hardness was determined by Monsanto hardness 
tester (Jyoti Scientific Laboratories, Gwalior). 
Friability and weight variation 
Friability test was carried out on 10 tablets. Initial weight 
of the tablets was measured and subsequently placed in 
chamber of friabilator (Roche friabilator) at 25 rpm speed 
for 4 min. After that tablets were de-dusted, reweighed and 
% friability was calculated. From each batch twenty tablets 
weight were noted using electronic balance. Their average 
weight (WA) was calculated. Percentage weight variation 
and average weights of the tablets along with standard 
deviation values were calculated using formulae given 
below. 
% Weight variation= (WA-WT)/WA 
Wetting time 
Another important parameter is wetting time. Five circular 
tissue papers of 10 cm diameter were placed in a Petri dish 
of a 10 cm diameter. 10 ml of water containing eosin, a 
water- soluble dye, was added to Petri dish. A tablet was 
carefully placed on the surface of the tissue paper. The time 
required for water to reach upper surface of the tablet is 
noted as wetting time15. 
Disintegration time 
Disintegration test is determined using the USP device used 
to test disintegration comprises six glass tubes that are 3” 
long, open at the top, and held against 10” screen at the 
bottom end of the basket rack assembly. One tablet is 
placed in each tube and the basket rack is positioned in 
beaker containing 900 ml of PBS (pH 6.8) at 37±2°C, such 
that the tablets remain below the surface of the liquid on 
their upward movement and descend not closer than 2.5cm 
from the bottom of the beaker. The disintegration time was 
recorded at the point at which tablet completely 
disintegrated. 
Drug content  
Ten tablets were weighed and powdered. An amount of the 
powder equivalent to 10 mg of Telmisartan was dissolved 
in 100 ml of pH (6.8) phosphate buffer, filtered, diluted 
suitably and analyzed for drug content at 296 nm using UV 
Visible spectrophotometer (UV-1800, Shimadzu, Japan) 16. 
In vitro drug release study and Release kinetics 
In vitro drug release studies of all formulations were 
carried out using paddle type tablet dissolution test 
apparatus (USP XXII type) at 50 rpm. The dissolution 
media, phosphate buffer pH (6.8) was maintained at 
37.0±0.50C. Samples were withdrawn at different intervals, 
diluted suitably and analyzed at 296 nm for cumulative 
drug release using UV-Visible spectrophotometer (UV-
1800, Shimadzu, Japan). The percentage of Telmisartan 
dissolved from tablet was calculated and the graph was 
plotted by time Vs % of drug dissolved16. 
The in vitro drug release data is fitted to various release 
kinetic models like zero order, first order, Higuchi matrix, 
Hixson- crowell and KorseMeyer-Peppas kinetic model. 
The coefficient of correlation (R2) values were calculated 
from the regression analysis of above plots. 
RESULTS AND DISCUSSION  
Solubility study 
The solubility of pure drug in water was found to be 0.056 
mg/ml which suggest that Telmisartan is practically 
insoluble in water, hence shows lower bioavailability. In 
present study solid dispersion of Telmisartan is prepared 
with PEG 6000 in ratios 1:1, 1:2, 1:3, 1:4, 1:5. The solubility 
of these dispersions were found 4.21, 7.91, 15.62, 22.38, 
19.46 mg/ml and 9.65, 13.66, 19.21, 28.67, 22.42 mg/ml in 
distilled water and PBS (pH 6.8) respectively. Result 
suggests that solubility of Telmisartan is increased with 
respect to the concentration of PEG 6000 till 1:4 and it 
started decreasing thereafter.  
 
Figure 1: Solubility profile of solid dispersion 
Infrared spectroscopy 
The FTIR studies were carried out to investigate the 
possible interaction between the Telmisartan and PEG 
6000 in the solid dispersion formulation. The FTIR spectra 
of pure drug, PEG 6000, and its solid dispersion shows no 
possible interaction between drug and carrier, which 
confirms the stability of drug in its solid dispersion. Solid 
dispersion brings characteristic change in the Telmisartan 
from crystalline to amorphous by dispersing in PEG 6000, 
which leads to solubility enhancement and improvements 
of flow properties. 
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Figure 2:  Fourier transform infrared (FTIR) spectra of Telmisartan, PEG 6000, and solid dispersion 
 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) measurements was 
performed on Telmisartan, PEG 6000, and its solid 
dispersion using a DSC (JADE DSC-6, PYRIS, USA) to 
analyse the thermal behaviour. The DSC thermogram of 
Telmisartan exhibited (fig. 2) an endothermic peak at 
2630C, which corresponds to the melting point of the 
Telmisartan. The carrier PEG 6000 showed an endothermic 
peak at 63.060C, which corresponds to the melting point of 
PEG 6000. There were only one endothermic peak 
observed for solid dispersion prepared using drug:carrier 
1:4 at 58.060C. The disappearance of endothermic peak of 
Telmisartan in solid dispersion gives an idea that 
Telmisartan might being dissolve state in melted PEG 6000. 
Solid dispersion shows weakness of endothermic peak at 
the melting point of drug. This could be attributed to higher 
PEG 6000 concentration and uniform distribution of drug 
in the crust of PEG 6000 resulting in complete miscibility of 
molten drug in PEG 6000. The disappearance of 
endothermic peak in solid dispersion formulations 
confirms the amorphous state of drug in prepared solid 
dispersion formulations. 
 
 
Figure 3: Differential scanning calorimetry (DSC) thermogram of Telmisartan, PEG 6000, and solid dispersion 
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Drug content analysis 
Percentage drug content of various solid dispersion 
formulations i.e. TSD1, TSD2, TSD3, TSD4, and TSD5 were 
found to be 92.94±0.48%, 94.35±0.57%, 96.78±0.78%, 
98.34±0.76%, and 96.62±0.87% respectively. The 
percentage drug content found 100±5% for all solid 
dispersion formulations. It was graphically represented 
in fig. 4.   
 
Figure 4: % Drug content of solid dispersion 
Formulation of ODTs using solid dispersion 
From above study of solid dispersion preparation of 
Telmisartan with PEG 6000 it was found that solid 
dispersion ratio TSD4 (1:4) has maximum solubility and 
drug content, is selected for further preparation of ODTs 
with addition of Superdisintegrants i.e. kyron T-314, 
croscarmellose sodium and sodium starch glycolate, 
taken in various ratios to find the optimum concentration 
of the Superdisintegrants required to yield formulation 
having least wetting time and disintegration time.   
Evaluation of ODTs 
Micromeritic studies 
Micromeritic properties of powder reflect the 
appropriateness of formulation. Hence, micromeritic 
properties of the drug excipients mixture were studied in 
term of bulk density, tapped density, car’s index and 
angle of repose to establish the flow property. The car’s 
index of all the formulations was found to be in the range 
from 15.15 % to 20.58%. The hausner’s ratio was found 
to be in the range from 1.17 to1.25 (i.e. less than 1.25) 
which indicates good flow properties. Angle of repose 
was found to be 25.76 to 30.21 degree (Table 2). The 
micromeritic properties of pure drug doesn’t show the 
free flow of powder for compression but when the solid 
dispersion of the Telmisartan is prepared with PEG 6000 
and mixed with other excipients and evaluated for 
micromeritic properties shows free flow ability and 
compressibility for direct compression. PEG 6000 alters 
the particle size and shape of drug particles from 
crystalline to spherical resulting in enhancement of flow 
ability and compressibility. 
 
Table 2: Micromeritic Studies of Various Powder Blend Formulations 
Batch Angle of repose  Bulk density Tapped density %Compressibility Hausner ratio 
TF1 26.99±1.71 0.54±0.06 0.68±0.07 20.58±1.10 1.25±0.01 
TF2 26.23±1.50 0.54±0.02 0.65±0.02 16.92±0.41 1.20±0.03 
TF3 25.76±0.22 0.56±0.06 0.67±0.05 16.41±1.20 1.19±0.08 
TF4 27.06±1.71 0.54±0.04 0.67±0.04 19.40±1.31 1.24±0.08 
TF5 28.91±0.20 0.57±0.09 0.69±0.07 17.39±0.98 1.21±0.02 
TF6 30.21±0.01 0.50±0.04 0.62±0.03 19.35±1.24 1.24±0.07 
TF7 30.05±0.98 0.51±0.01 0.62±0.01 17.74±0.71 1.21±0.09 
TF8 29.53±0.21 0.56±0.04 0.66±0.06 15.15±0.23 1.17±0.02 
TF9 29.21±0.56 0.50±0.02 0.61±0.09 18.03±0.28 1.22±0.07 
Values are expressed as mean ± S.D., n=3 
Thickness and hardness 
All the prepared tablets are characterized by their size and 
shape, which found round shape and uniform thickness in 
the range of 3.36 to 3.85 mm. The hardness of formulations 
was found within the range of 4.12 to 4.48 kg/cm2.  
Friability and weight variation 
Friability for all formulations was found to be less than 1%. 
This is the acceptable limit. The result shows resistance to 
loss of weight indicated the tablet ability to withstand 
abrasion in handling, packaging and shipment. 
The weight variation of tablets was determined according 
to the specification in USP and all the tablets were found to 
comply with specification. Weight of the tablets was found 
in the range of (±5%) variation. 
Wetting time 
Wetting time for ODTs depends on the concentration of 
Superdisintegrants. We have used three types of 
Superdisintegrants i.e. kyron T-314, croscarmellose 
sodium and sodium starch glycolate in the concentration 
range of 4% to 6%. The wetting time for all formulations 
was 40.6 to 29.3 sec for kyron T-314 containing 
formulation, 59.1 to 49.9 sec for croscarmellose sodium 
containing formulation, and 66.1 to 58.3 sec for sodium 
starch glycolate containing formulation. The least wetting 
time amongst all formulation is found with TF3 
formulation which contains 6% kyron T-314. Kyron T-314 
is a crosslinked polymer of Polycarboxylic acids breaks the 
tablets into very smaller particles, thus it increases the 
effective surface area for the absorption of the active 
substances and ultimately it increases the dissolution and 
bioavailability of the active substances. Its 4.0% to 6.0% 
quantity is sufficient for dissolution improvement and 
suitable for direct compression. It also provide smooth 
cream-like mouth feel, so more suitable for ODTs.  All the 
results of wetting time of all formulations are shown in 
table 3. This has a very high swelling tendency of hydration 
either in contact with water or G.I. fluids causing very fast 
wetting of the tablets. 
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Figure 5: Wetting and disintegration time of various Orodispersible tablets prepared 
 
Disintegration time 
Another fact for ODTs which is much more important is 
disintegration time of the tablets. According to European 
pharmacopoeia ODTs required less than 3 minute in 
disintegration. In the present study, all the tablets 
disintegrated in approximately in 1 minute. Disintegration 
time for all formulations was found between 28.8 to 24.1 
sec for kyron T-314 containing formulation, 52.8 to 61.1 
sec for croscarmellose sodium containing formulation, and 
56.3 to 38.3 sec for sodium starch glycolate containing 
formulation (Table 3). In amongst all Superdisintegrants 
kyron T-314 show faster disintegration time for tablets (for 
TF3 24.1 sec) this is because it has a very high swelling 
tendency of hydration either in contact with water or G.I. 
fluids causing fast disintegration without the formation of 
lumps and thus acts as an effective tablet 
Superdisintegrant. The porous structure of the tablets is 
responsible for faster water uptake resulting in fast 
disintegration.
 
Table 3: Evaluation Parameters of Various Orodispersible Tablets 
Batch    Friability (%)  Wetting time(sec) Disintegration time (sec) %Drug     content         
TF1   0.82±0.67    40.6±2.22   28.8±1.89 96.82±0.51 
TF2   0.62±0.68    36.0±3.30   26.2±1.90 98.21±0.78 
TF3   0.52±0.94    29.3±1.01   24.1±0.90 99.67±0.27 
TF4   0.69±0.21    59.1±1.02   53.1±1.22 97.61±0.82 
TF5   0.83±0.73    53.2±0.08   42.3±2.22 95.61±0.10 
TF6   0.69±0.83    49.9±.62   36.1±0.45 98.24±0.36 
TF7   0.72±0.93    66.1±1.78   52.8±0.34 96.45±0.92 
TF8   0.66±0.41    61.8±0.51   50.0±1.41 97.81±0.30 
TF9   0.59±0.01    58.3±0.22   61.1±1.92 96.67±0.60 
Values are expressed as mean ± S.D., n=3 
 
Drug content 
Percentage drug content for various formulations i.e. TF1, 
TF2, TF3, TF4, TF5, TF6, TF7, TF8, TF9 were found to be 
96.82%, 98.21%, 99.67%, 97.61%, 95.61%, 98.24%, 
96.45%, 97.81%, 96.67% respectively. The percentage 
drug content was found to be in the USP limits for all 
formulations. The % drug content for all formulations is 
represented in table 3. 
 
 
Figure 6: % Drug content of formulations 
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In vitro drug release study 
The release characteristics of ODTs was studied using 
tablet dissolution test apparatus is paddle type (USP XXII 
type) at 50 rpm. 900 ml of Phosphate buffer pH (6.8) was 
used as the dissolution media at 37.0±20C. The cumulative 
percentage drug release of formulations i.e. TF1, TF2, TF3, 
TF4, TF5, TF6, TF7, TF8, TF9 were 97.72%, 96.92%, 
99.93%, 95.82%, 92.87%, 89.01%, 90.56%, 93.81%, 
95.28% respectively in 30 minute. All the results of 
Cumulative percentage drug release of all formulations 
graphically represented in fig. 7. Formulation TF3 
containing kyron T-314 shows better drug release profile 
99.93%.
 
 
Figure 7: Cumulative % drug releases of different formulations 
 
The in-vitro drug release profile of various optimized 
formulations were studied for release kinectics with 
respect to zero order, first order, Higuchi, Hixson crowell 
and Korsemeyer-peppas model (Table 4). The R2 for 
various kinetics models for optimized formulation TF3 was 
found 0.999, 0.654, 0.988, 0.972, 0.968 respectively which 
is closer to one, partially for Zero order model is very close 
to one. The diffusional exponent, n characterizes the 
mechanism of drug release. It is known that for non-
swelling tablets, the drug release can generally be 
expressed by the Fickian diffusion mechanism, for which n 
= 0.5. For non-Fickian release, the n value falls between 0.5 
and 1.0 [0.5 < n < 1.0]; whereas in the case super case II 
transport n >1. The value of n for all formulations is in the 
range from 0.151 to 0.516. Which conclude that all 
formulation follow fickian diffusion mechanism. 
 
 
Figure 8: Zero order Release kinetics of various solid dispersion formulations 
TABLE 4: Release Kinetics of Various Orodispersible Tablets 
Formu- 
lations  
Zero order First order Higuchi kinetic Hixson-
Crowell kinetic 
Korse Meyer-Peppas 
kinetic 
R2 R2 R2 R2 R2 n 
TF1 0.587 0.885 0.698 0.777 0.778 0.151 
TF2 0.956 0.959 0.991 0.991 0.997 0.121 
TF3 0.923 0.930 0.974 0.986 0.992 0.105 
TF4 0.971 0.918 0.969 0.967 0.947 0.124 
TF5 0.983 0.954 0.987 0.977 0.989 0.242 
TF6 0.978 0.938 0.975 0.963 0.987 0.516 
TF7 0.945 0.992 0.978 0.984 0.980 0.492 
TF8 0.973 0.928 0.979 0.968 0.978 0.412 
TF9 0.999 0.654 0.988 0.972 0.968 0.136 
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CONCLUSION  
The method utilized for the preparation of ODTs was 
simple and reproducible. ODTs of Telmisartan prepared 
with addition of solid dispersion technique by solvent 
evaporation method with PEG 6000 and 
Superdisintegrants like kyron T-314, croscarmellose 
sodium and sodium starch glycolate. Formulation 
containing 6% of Kyron T-314 shows least wetting time 
and disintegration time. Which indicates that kyron T-314 
is suitable disintegrant for ODTs.  
The results of the study establish the Telmisartan ODTs as 
a potential drug delivery system for effective management 
of hypertension with improved patient compliance.  
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